Company Profile For Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline.

BRIEF: For the nine months ended 30 September 2009, Dynavax Technologies Corporation's revenues increased 52% to $38.1M. Net loss decreased 99% to $295K. Revenue reflects an increase in collaboration revenue and a hike in grant revenues. Net loss reflects a decrease in research & development expenses, lower general & administrative expenses, a decrease in interest expense and a decline in non controlling interest in SDI.